

# Susanne Sauãele

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7351781/publications.pdf>

Version: 2024-02-01

35  
papers

3,422  
citations

430442

18  
h-index

395343

33  
g-index

35  
all docs

35  
docs citations

35  
times ranked

3217  
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. <i>Leukemia</i> , 2022, 36, 1834-1842.	3.3	10
2	Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases. <i>Annals of Hematology</i> , 2022, 101, 1825-1834.	0.8	7
3	Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response. <i>Hematologic Malignancies</i> , 2021, , 265-273.	0.2	0
4	Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMRâ€”final report from AFTER-SKI. <i>Leukemia</i> , 2021, 35, 2416-2418.	3.3	13
5	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. <i>Leukemia</i> , 2021, 35, 1344-1355.	3.3	43
6	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	0.6	147
7	Chronic myeloid leukaemia. <i>Lancet, The</i> , 2021, 398, 1914-1926.	6.3	65
8	Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response. <i>Blood</i> , 2021, 138, 3608-3608.	0.6	3
9	FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study. <i>Blood</i> , 2021, 138, 633-633.	0.6	10
10	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. <i>Blood</i> , 2021, 138, 1476-1476.	0.6	1
11	The vascular bone marrow niche influences outcome in chronic myeloid leukemia <i>via</i> the E-selectin - SCL/TAL1 - CD44 axis. <i>Haematologica</i> , 2020, 105, 136-147.	1.7	44
12	Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. <i>Acta Haematologica</i> , 2020, 143, 217-231.	0.7	26
13	Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. <i>Leukemia</i> , 2020, 34, 2113-2124.	3.3	22
14	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. <i>Leukemia</i> , 2020, 34, 2125-2137.	3.3	47
15	DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1177.	1.8	20
16	Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020, 99, 991-1006.	0.8	3
17	Efficacy and Safety Results from ASCSEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	ARTICLE	IF	CITATIONS
19	Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. PLoS ONE, 2019, 14, e0214305.	1.1	16
20	Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia. Blood, 2019, 134, 1647-1647.	0.6	3
21	Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. Journal of Cancer Research and Clinical Oncology, 2018, 144, 945-954.	1.2	124
22	Effect of ABCG2 , OCT1 , and ABCB1 ( MDR1 ) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 266-271.	0.2	18
23	Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia, 2018, 32, 1222-1228.	3.3	22
24	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncology, The, 2018, 19, 747-757.	5.1	444
25	Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. Cancer Research, 2018, 78, 6223-6234.	0.4	16
26	The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia. PLoS ONE, 2018, 13, e0196326.	1.1	7
27	Management of CML-blast crisis. Best Practice and Research in Clinical Haematology, 2016, 29, 295-307.	0.7	60
28	Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?. Journal of Clinical Oncology, 2014, 32, 2821-2823.	0.8	122
29	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology, 2014, 32, 415-423.	0.8	271
30	Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Annals of Hematology, 2014, 93, 71-80.	0.8	60
31	Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Annals of Hematology, 2014, 93, 1167-1176.	0.8	21
32	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884.	0.6	1,743
33	Clinical Trials in Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports, 2012, 7, 109-115.	1.2	3
34	Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV. Blood, 2008, 112, 184-184.	0.6	8
35	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV. Blood, 2008, 112, 448-448.	0.6	3